US Stock MarketDetailed Quotes

RXRX Recursion Pharmaceuticals

Watchlist
  • 8.920
  • +0.340+3.96%
Close Apr 11 16:00 ET
  • 8.870
  • -0.050-0.56%
Pre 07:35 ET
2.09BMarket Cap-5645P/E (TTM)

About Recursion Pharmaceuticals Company

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Company Profile

SymbolRXRX
Company NameRecursion Pharmaceuticals
Listing Date04/16/2021
Issue Price18.00
Founded2013
CEODr. Christopher Gibson, PhD
MarketNASDAQ
Employees500
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address41 South Rio Grande Street
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84101
Phone1-385-269-0203

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christopher Gibson, PhD
  • Chief Executive Officer and Director
  • 6.32M
  • Dr. David J. Mauro, M.D.
  • Chief Medical Officer
  • --
  • Tina Marriott Larson
  • President and Chief Operating Officer
  • 2.76M
  • Dr. Michael Secora, PhD
  • Chief Financial Officer and Principal Accounting Officer
  • 2.09M
  • Matthew Kinn
  • Chief Corporate Development Officer
  • --
  • Ramon Martin Chavez, PhD
  • Chairman of the Board
  • 318.14K
  • Dr. Robert M. Hershberg, M.D.,PhD
  • Independent Director
  • 293.14K
  • Terry-Ann Burrell
  • Independent Director
  • 298.14K
  • Dean Y. Li
  • Independent Director
  • 290.64K
  • Zachary Bogue, J.D.
  • Independent Director
  • 42.49K
  • Dr. Blake Borgeson, PhD
  • Independent Director
  • 283.14K
  • Zavain Dar, PhD
  • Independent Director
  • 298.14K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg